Roche Licenses Simcere’s SIM0660

Companies: Roche / Simcere Zaiming · Asset: SIM0660 (CD79axCD19xCD3 Trispecific) · Deal Terms: $75M Upfront + up to $1.455B Milestones · Territory: Worldwide · Date: September 1, 2026 Summary Roche licensed exclusive global rights to Simcere Zaiming’s SIM0660, a CD79axCD19xCD3 trispecific T-cell engager intended for…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Astellas / AviadoBio – Gene Therapy Program Sustained via Nonprofit Funding
Samsung Biologics Moves Into Peptide Manufacturing
Boulevard Bio Launches with $65 Million
GSK – $1B SiranBio Oligo Deal